297 related articles for article (PubMed ID: 25557632)
1. Mycophenolic acid in dermatology a century after its discovery.
Strathie Page SJ; Tait CP
Australas J Dermatol; 2015 Feb; 56(1):77-83. PubMed ID: 25557632
[TBL] [Abstract][Full Text] [Related]
2. Mycophenolate mofetil in dermatology.
Orvis AK; Wesson SK; Breza TS; Church AA; Mitchell CL; Watkins SW
J Am Acad Dermatol; 2009 Feb; 60(2):183-99; quiz 200-2. PubMed ID: 19150270
[TBL] [Abstract][Full Text] [Related]
3. Mycophenolate mofetil.
Zwerner J; Fiorentino D
Dermatol Ther; 2007; 20(4):229-38. PubMed ID: 17970888
[TBL] [Abstract][Full Text] [Related]
4. [Mycophenolate mofetil: a new immunosuppressive drug in dermatology and its possible uses].
Geilen CC; Orfanos-Boeckel H; Offermann G; Orfanos CE
Hautarzt; 2000 Feb; 51(2):63-9. PubMed ID: 10743574
[TBL] [Abstract][Full Text] [Related]
5. Mycophenolate in dermatology.
Liu V; Mackool BT
J Dermatolog Treat; 2003 Dec; 14(4):203-11. PubMed ID: 14660264
[TBL] [Abstract][Full Text] [Related]
6. Enteric-coated mycophenolate sodium: safe conversion from mycophenolate mofetil in maintenance renal transplant recipients.
Budde K; Glander P; Diekmann F; Dragun D; Waiser J; Fritsche L; Neumayer HH
Transplant Proc; 2004 Mar; 36(2 Suppl):524S-527S. PubMed ID: 15041401
[TBL] [Abstract][Full Text] [Related]
7. Mycophenolate mofetil: a dermatologic perspective.
Mydlarski PR
Skin Therapy Lett; 2005 Apr; 10(3):1-6. PubMed ID: 15986076
[TBL] [Abstract][Full Text] [Related]
8. Better mycophenolic acid 12-hour trough level after enteric-coated mycophenolate sodium in patients with gastrointestinal intolerance to mycophenolate mofetil.
Sánchez Fructuoso A; Calvo N; Moreno MA; Giorgi M; Conesa J; Barrientos A
Transplant Proc; 2007 Sep; 39(7):2194-6. PubMed ID: 17889135
[TBL] [Abstract][Full Text] [Related]
9. Mycophenolate mofetil in autoimmune and inflammatory skin disorders.
Nousari HC; Sragovich A; Kimyai-Asadi A; Orlinsky D; Anhalt GJ
J Am Acad Dermatol; 1999 Feb; 40(2 Pt 1):265-8. PubMed ID: 10025760
[TBL] [Abstract][Full Text] [Related]
10. Rediscovering mycophenolic acid: a review of its mechanism, side effects, and potential uses.
Kitchin JE; Pomeranz MK; Pak G; Washenik K; Shupack JL
J Am Acad Dermatol; 1997 Sep; 37(3 Pt 1):445-9. PubMed ID: 9308561
[TBL] [Abstract][Full Text] [Related]
11. Enteric-coated mycophenolate sodium: therapeutic equivalence to mycophenolate mofetil in de novo renal transplant patients.
Sollinger H
Transplant Proc; 2004 Mar; 36(2 Suppl):517S-520S. PubMed ID: 15041399
[TBL] [Abstract][Full Text] [Related]
12. Gastrointestinal quality of life improvement of renal transplant recipients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium drugs or agents: mycophenolate mofetil and enteric-coated mycophenolate sodium.
Ortega F; Sánchez-Fructuoso A; Cruzado JM; Gómez-Alamillo JC; Alarcón A; Pallardó L; Morales JM; Oliver J; Guinea G;
Transplantation; 2011 Aug; 92(4):426-32. PubMed ID: 21760569
[TBL] [Abstract][Full Text] [Related]
13. Mycophenolate mofetil versus enteric-coated mycophenolate sodium: a large, single-center comparison of dose adjustments and outcomes in kidney transplant recipients.
Sollinger HW; Sundberg AK; Leverson G; Voss BJ; Pirsch JD
Transplantation; 2010 Feb; 89(4):446-51. PubMed ID: 20177347
[TBL] [Abstract][Full Text] [Related]
14. Gastrointestinal side effects in liver transplant recipients taking enteric-coated mycophenolate sodium vs. mycophenolate mofetil.
Lopez-Solis R; DeVera M; Steel J; Fedorek S; Sturdevant M; Hughes C; Humar A
Clin Transplant; 2014 Jul; 28(7):783-8. PubMed ID: 24754682
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of tolerability and ability to increase immunosuppression in renal transplant patients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium.
Bilodeau JF; Montambault P; Wolff JL; Lemire J; Masse M
Transplant Proc; 2009 Nov; 41(9):3683-9. PubMed ID: 19917367
[TBL] [Abstract][Full Text] [Related]
16. Mycophenolates in transplantation.
Sollinger HW
Clin Transplant; 2004 Oct; 18(5):485-92. PubMed ID: 15344948
[TBL] [Abstract][Full Text] [Related]
17. Renal transplant patients with gastrointestinal intolerability to mycophenolate mofetil: conversion to enteric-coated mycophenolate sodium.
Calvo N; Sanchez-Fructuoso AI; Conesa J; Moreno A; Barrientos A
Transplant Proc; 2006 Oct; 38(8):2396-7. PubMed ID: 17097945
[TBL] [Abstract][Full Text] [Related]
18. Safety assessment of the conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable renal transplant recipients.
Massari P; Duro-Garcia V; Girón F; Hernández E; Juárez F; Castro C; Toledo M;
Transplant Proc; 2005 Mar; 37(2):916-9. PubMed ID: 15848574
[TBL] [Abstract][Full Text] [Related]
19. Similar efficacy and safety of enteric-coated mycophenolate sodium (EC-MPS, myfortic) compared with mycophenolate mofetil (MMF) in de novo heart transplant recipients: results of a 12-month, single-blind, randomized, parallel-group, multicenter study.
Kobashigawa JA; Renlund DG; Gerosa G; Almenar L; Eisen HJ; Keogh AM; Lehmkuhl HB; Livi U; Ross H; Segovia J; Yonan N;
J Heart Lung Transplant; 2006 Aug; 25(8):935-41. PubMed ID: 16890114
[TBL] [Abstract][Full Text] [Related]
20. Use of enteric-coated mycophenolate sodium in liver transplant patients with intestinal intolerance caused by mycophenolate mofetil.
Doria C; Ramirez CB; Frank AM; Vaccino S; Fraser N; Marino IR
Clin Transplant; 2009; 23(6):882-6. PubMed ID: 19573090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
